Infantile spasm is also known as the West syndrome. It is a rare seizure disorder that can occur in epilepsy patients in childhood and infancy. Infantile spasm is usually initiated between four and eight months old. This condition is found in approximately 2% of childhood epilepsies, and 25% of those that begin in the first year. Each year, the U.S. diagnoses between 2,000 and 4,000 new cases. Half to seventy percent of infantile spasms sufferers are affected by other types, while nearly 18% to fifty percent develop Lennox-Gastaut Syndrome or other forms of symptomatic generalized seizures. There are only two FDA-approved medical treatment options available in the market-adrenocorticotropic hormone and vigabatrin. Market growth for infantile spasms therapeutics is expected to increase in the period 2021-2028. Data Bridge Market Research analyzes the market to determine that it will grow at a rate of 10% over the forecast period. Infantile spasm, also known as West Syndrome, is a rare type of epilepsy. This condition is characterized by the occurrence of brief and subtle seizures in infants.
The spasm causes the body to stiffen suddenly, with the arms, legs, and head bending forward, and the back arching. This condition can be caused by brain tumors, brain infection, birth injury, or genetic or chromosomal abnormalities. Infantile spasms therapy is used to treat seizures and epilepsy in children under one year of age. An infantile spasm is a sudden stiffening or forward bending in the head, arms, and legs. The primary treatments for infantile spasms are steroid therapy, and Sabril, an anti-seizure medication. Because Dr. William James West first described the condition in the 1840s, infantile spasms have been called the West syndrome. Two to three percent of all 10,000 babies experience these spasms in their first year. They usually occur between three and eighteen months of age. This disorder is more common among boys than it is among girls. Another cause is family history. About 3% to 66% of cases can be attributed to this. Infantile spasms are diagnosed by neurological and physical examinations, blood and urine tests, as well as laboratory tests like MRI of the brain. Monotherapy and combination therapy are both possible. About 20% to 50% of patients develop infantile spasms into the Lennox–Gastaut syndrome. A similar proportion of Lennox-Gastaut patients have had infantile spasms in the past.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Infantile Spasma Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Infantile Spasma Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.